Director Michael Stansky Buys $1.48M in Shares at Public Offering Price Following Recent Dilution
TLSI sits 51% above its 52-week low of $3.42.
Summary
Director Michael P. Stansky purchased $1.48 million worth of TriSalus Life Sciences common stock at $4.10 per share, matching the price of the company's recent public offering.
Key Events · Ownership and Investor Activity · TLSI
-
Significant Insider Purchase
Director Michael P. Stansky acquired 361,098 shares of common stock for a total value of $1,480,502 through open market purchases.
-
Purchase Price Aligns with Recent Offering
The shares were purchased at $4.10 each, which is the same price as the company's public offering finalized on February 20, 2026, indicating strong conviction following the capital raise.
-
Increased Ownership Stake
Following these transactions, Mr. Stansky's total holdings in TriSalus Life Sciences, both direct and indirect, increased to 787,132 shares.
Analysis · TLSI · Industrial Applications And Services
Director Michael P. Stansky's substantial open market purchase of over $1.48 million in TriSalus Life Sciences shares at $4.10 each is a strong vote of confidence, especially as it matches the price of the recent public offering. This insider buying, occurring just days after the company raised $40 million through a dilutive offering, signals that a key board member sees value at the offering price and is willing to increase their stake. Investors may view this as a positive indicator, suggesting the director believes the company is well-positioned post-capital raise.
At the time of this filing, TLSI was trading at $5.16 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $249.3M. The 52-week trading range was $3.42 to $7.95. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.